Skip to main content

Table 1 Pathological and clinical characteristics of the inflammatory breast cancer (IBC) cohort

From: Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer

  IBC
Total, n (%) 156 (100)
Age (years)
 Median 53
 Range 23–84
  ≤50, n (%) 63 (40.5)
  >50, n (%) 93 (59.5)
Sex, n (%)
 Female 156 (100)
 Male 0 (0)
Stage, n (%)
 III 120 (76.9)
 IV 36 (23.1)
ER status, n (%)
 Negative 89 (57.1)
 Positive 67 (42.9)
PR status, n (%)
 Negative 111 (71.2)
 positive 45 (28.8)
Her2 status, n (%)
 Negative 113 (72.4)
 Positive 43 (27.6)
Subgroups, n (%)
 TNBC 51 (32.7)
 HR/Her2+ 33 (21.2)
 HR+/Her2 62 (39.7)
 HR+/Her2+ 10 (6.4)
Distant metastases, n (%)
 Yes 98 (62.8)
 No 58 (37.2)
SBR histological grade, n (%)
 I 2 (1.3)
 II 63 (40.4)
 III 91 (58.3)
  1. ER estrogen receptor, Her2 human epidermal growth factor receptor 2, HR hormone receptor, PR progesterone receptor, SBR Scarf Bloom Richardson classification, TNBC triple-negative breast cancer